Ending 23andMe’s Drug Discovery Dream: What Went Wrong?
23andMe, the genetics company that many people have been excited about, recently made a big announcement. The company has decided to stop working on creating new medicines and will be letting go of 40%...
Implications of a Second Trump Term on Hospitals, Insurers, and Medicare
The healthcare industry has always been a money-making machine, regardless of who is leading the country. It continues to consume the hard-earned savings, wages, and tax dollars of patients and healthcare workers. The cost...
Understanding and Addressing Cardiovascular Health Disparities: Insights from Recent Studies
The recent election results may have shifted focus away from diversity, equity, and inclusion, but new research papers emphasize the importance of addressing health disparities based on socioeconomic factors. These papers, set to be...
Navigating Sickle Cell Pain, Loss, and Survival in America
Today, I want to talk about Tammy Clemons, a woman who is navigating the challenges of living with sickle cell disease in America. Tammy's story is one of pain, loss, and survival, and it...
FDA Plans to Ban Cold Medicine, Eisai’s Alzheimer’s Drug Sales, and More: Pharmalittle Update
As we approach the end of another workweek, it's time to start thinking about weekend plans. Our schedule includes tending to the Pharmalot grounds, spending time with our beloved mascots, and catching up on...
GSK Withdraws from BIO, Signaling Major Setback for Lobbying Group
Pharmaceutical company GSK has announced its decision to leave the Biotechnology Innovation Organization (BIO), which is the largest trade group in the biotechnology industry. This move by GSK marks a significant setback for the...
The Impact of Trump’s Return on NIH Funding and Politicization: What to Expect
After Donald Trump's election win, National Institutes of Health director Monica Bertagnolli addressed the agency's employees, emphasizing the organization's long-standing commitment to biomedical research for public health. Despite reassurances from the NIH, concerns are...
Navigating the Corporate Ladder: Recent Changes and Updates in the Industry
The pharmaceutical industry is always buzzing with changes and updates, and it's important to stay in the loop. Whether a new hire, promotion, or an exciting development, sharing news about who is coming and...
Biotech Analyst and CEO Discuss Election Results: Insights from Brian Skorney and Daphne Zohar
Biotech analyst Brian Skorney and biotech executive Daphne Zohar recently appeared on "The Readout LOUD" podcast to share their thoughts on how the outcomes of the recent election may impact the biotech industry. They...
Exploring Trump and RFK Jr.’s Impact on Healthcare: Possibilities and Limitations
Republicans are gearing up to take charge in Washington, with high hopes of turning their healthcare goals into reality. After years of being overshadowed by a Democratic White House and Senate, congressional Republicans and...
RFK Jr. Seeks Public Input for Trump’s Health Team Selection
President-elect Donald Trump and his team face the daunting task of appointing 4,000 individuals to staff his administration before Inauguration Day. Robert F. Kennedy Jr., a Trump campaign surrogate and advocate for "Make America...
Navigating Trans Health Care in the Trump Administration: Challenges and Strategies
President-elect Donald Trump's campaign targeted transgender individuals, spending significant funds on anti-trans ads. He criticized gender-affirming care for young trans people, calling it "left-wing gender insanity" and "child abuse." Now, as he prepares to...